
Cobenfy revived shelved muscarinic therapy for schizophrenia, easing side effects while boosting negative and cognitive symptoms across trials.

Cobenfy revived shelved muscarinic therapy for schizophrenia, easing side effects while boosting negative and cognitive symptoms across trials.

Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.

Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.

Explore how TMS might be useful in treating schizophrenia, and how researchers are working to localize target areas.

Causal lesion and stimulation studies map psychosis to hippocampus–thalamus circuits, pointing to a reproducible TMS target for schizophrenia symptoms.

Adolescent synaptic pruning may fuel schizophrenia; researchers explore how restoring plasticity could ease fixed delusions.

Primate brain tissue studies track pruning, myelination, and dopamine across development, revealing adolescence-linked neural dynamics that may explain schizophrenia risk.

Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.

Real-world data highlights Lybalvi’s impact on acute care use in high-risk patients and Aristada’s long-acting dosing for steadier schizophrenia treatment.

Brenipatide being investigated for alcohol use disorder, while exploring relapse prevention in recurrent depression and other psychiatric conditions.

Phase 1 brenipatide shows week-long exposure and tolerable GI effects, fueling studies in alcohol and other substance use disorders.

Learn how early antidepressant response guides faster treatment changes in major depression, with earlier use of esketamine, TMS, and ECT despite insurance barriers.

Learn how experts distinguish agitation from psychosis in Alzheimer disease, weigh new FDA options, and apply evidence for off-label care.

Three posters presented at APA 2026 detail real-world treatment patterns, pooled long-term cardiometabolic safety, and urinary adverse event rates with xanomeline and trospium chloride.

From long-acting antipsychotics to psilocybin and new ADHD meds, clinicians weigh emerging therapies reshaping depression and postpartum care.

How can new Alzheimer therapies benefit patients today?

Consensus definition clarifies Alzheimer agitation, reviews FDA-approved brexpiprazole and dextromethorphan-bupropion, and spotlights caregiver burden

Explore next-gen depression therapies targeting neuroplasticity and why biomarkers may unlock precision psychiatry for MDD.

ASCP updates spotlight ketamine safety guardrails, at‑home agitation therapy, psilocybin phase 3 momentum, and biomarker-driven precision psychiatry.

Top 2026 psychiatry conference takeaways: mixed-feature bipolar care, GLP-1 addiction trials, schizophrenia adherence, TD gaps, AI prodrome screening.

SIRS highlights new schizophrenia advances: LB-102 shows promise, Cobenfy switching stays stable, and tazbentetol targets synaptic regeneration.

COMP360 psilocybin shows rapid, durable gains in treatment‑resistant depression, as psychedelics continue to grow.

Where can vagus nerve stimulation fit into treating depression?

New primate data show IV tau-silencing gene therapy cuts brain tau up to 75% with liver-sparing safety, clearing path for 2026 trial.

Motivational interviewing can help psychiatrists address long-acting injectable hesitancy in schizophrenia, according to Gerald Maguire, MD.

How do you pick an LAI antipsychotic? Molecule first, delivery system second, Jacob Hanaie, PharmD, shared at SoCal Psychiatry.

Phase 3 COMP360 psilocybin data show lasting TRD relief; experts explain brain-network reset, therapy support, and what approval could mean.

At the Southern California Psychiatry Conference, Jason Kellogg, MD, shares insights into the evolution of the MDD pipeline, with an eye on rapid-acting novel mechanisms.

Why sleep checks matter in ADHD: spot apnea, executive dysfunction, and hidden ADHD behind treatment-resistant depression.

Learn about screening for postpartum depression and available pharmacological treatments.